

LETAIRIS (ambrisentan)

## **Pre - PA Allowance**

None

## **Prior-Approval Requirements**

Age 18 years of age or older

#### Diagnosis

Patient must have the following:

- 1. Pulmonary Arterial Hypertension (PAH) WHO Group I
  - a. NYHA functional classification of physical activity Class II or III
  - b. Absence of clinically significant anemia
  - c. Prescribed by or recommended by a cardiologist or pulmonologist
  - d. Females of reproductive potential should have pregnancy excluded and agree to use acceptable method of contraception during therapy and for one month after stopping therapy
  - e. Absence of a concurrent diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
  - f. Prescriber agrees to monitor for pulmonary edema and discontinue if confirmed
  - g. **Brand Letairis only:** Patient **MUST** have tried the preferred product (generic Letairis: ambrisentan) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

### **Prior - Approval Limits**

Quantity90 tablets per 90 daysDuration2 years

# Prior – Approval Renewal Requirements

Age 18 years of age or older

#### Diagnosis

Patient must have the following:



LETAIRIS

- 1. Pulmonary Arterial Hypertension (PAH) WHO Group I
  - a. Symptoms have improved or stabilized
  - b. Females of reproductive potential should have pregnancy excluded and agree to use acceptable method of contraception during therapy and for one month after stopping therapy
  - c. Absence of a concurrent diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
  - d. Prescriber agrees to monitor for pulmonary edema and discontinue if confirmed
  - e. Brand Letairis only: Patient MUST have tried the preferred product (generic Letairis: ambrisentan) unless the patient has a valid medical exception (e.g. inadequate treatment response, intolerance, contraindication)

### Prior – Approval Renewal Limits

Same as above